JP2017524702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524702A5 JP2017524702A5 JP2017504046A JP2017504046A JP2017524702A5 JP 2017524702 A5 JP2017524702 A5 JP 2017524702A5 JP 2017504046 A JP2017504046 A JP 2017504046A JP 2017504046 A JP2017504046 A JP 2017504046A JP 2017524702 A5 JP2017524702 A5 JP 2017524702A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- inhibitor
- amino
- alkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, carboxy, amino Chemical group 0.000 claims description 50
- 239000003112 inhibitor Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 8
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 8
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims description 4
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 4
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 4
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 4
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 4
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 4
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 4
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 4
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 4
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 4
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003719 aurora kinase inhibitor Substances 0.000 claims description 4
- 230000005784 autoimmunity Effects 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000002860 competitive effect Effects 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 2
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 229950010817 alvocidib Drugs 0.000 claims description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 229960003982 apatinib Drugs 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- 229960003736 bosutinib Drugs 0.000 claims description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960003784 lenvatinib Drugs 0.000 claims description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- 229950003968 motesanib Drugs 0.000 claims description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims description 2
- 229950008835 neratinib Drugs 0.000 claims description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229950010203 nimotuzumab Drugs 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960001131 ponatinib Drugs 0.000 claims description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 229950001626 quizartinib Drugs 0.000 claims description 2
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229950006764 rigosertib Drugs 0.000 claims description 2
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- 229950009919 saracatinib Drugs 0.000 claims description 2
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims description 2
- 229950000055 seliciclib Drugs 0.000 claims description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229960000235 temsirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 229950005976 tivantinib Drugs 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 0 *C1(CNC2)[C@]2C1I Chemical compound *C1(CNC2)[C@]2C1I 0.000 description 13
- 238000000034 method Methods 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- SGLTYXRTDQXURA-UHFFFAOYSA-N C(CNC1)C11CNCCC1 Chemical compound C(CNC1)C11CNCCC1 SGLTYXRTDQXURA-UHFFFAOYSA-N 0.000 description 1
- PEAKYQNSMQTDFM-RSFRUGGISA-O CC(C(C(N(C1CCCC1)C1=C)=O)=C(C)/C1=C/N=C(\N)/NC(C=N1)=CN/C1=C\C(N1CCNCC1)=[NH2+])=O Chemical compound CC(C(C(N(C1CCCC1)C1=C)=O)=C(C)/C1=C/N=C(\N)/NC(C=N1)=CN/C1=C\C(N1CCNCC1)=[NH2+])=O PEAKYQNSMQTDFM-RSFRUGGISA-O 0.000 description 1
- YWCAUGNZFWIQFJ-SCGFUGMASA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(NC(C=C1)=CN/C1=C\C(\N1CCNCC1)=N/C)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(NC(C=C1)=CN/C1=C\C(\N1CCNCC1)=N/C)nc2)=O YWCAUGNZFWIQFJ-SCGFUGMASA-N 0.000 description 1
- JAGZDBZCJLVOFB-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)cc3c1c(N1CCNCC1)c[nH]3)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)cc3c1c(N1CCNCC1)c[nH]3)nc2)=O JAGZDBZCJLVOFB-UHFFFAOYSA-N 0.000 description 1
- ZXUGCYUTXACFQO-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc(CC3)c1N3C1CCNCC1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc(CC3)c1N3C1CCNCC1)nc2)=O ZXUGCYUTXACFQO-UHFFFAOYSA-N 0.000 description 1
- JSFSGWUSIIUSSD-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc(CCN3C)c1C3=O)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc(CCN3C)c1C3=O)nc2)=O JSFSGWUSIIUSSD-UHFFFAOYSA-N 0.000 description 1
- VBIUGAIAKASLIB-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc3c1[n](CN1CCNCC1)cc3)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(cc1)nc3c1[n](CN1CCNCC1)cc3)nc2)=O VBIUGAIAKASLIB-UHFFFAOYSA-N 0.000 description 1
- ZBHKUANAGSXJDY-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc1)cc3c1[n](C1CNC1)cc3)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc1)cc3c1[n](C1CNC1)cc3)nc2)=O ZBHKUANAGSXJDY-UHFFFAOYSA-N 0.000 description 1
- LXKLVECHQDLXSG-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc1)cc3c1[n](C1CNCC1)cc3)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc1)cc3c1[n](C1CNCC1)cc3)nc2)=O LXKLVECHQDLXSG-UHFFFAOYSA-N 0.000 description 1
- SEODMJGHAXQXJO-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc13)ccc1[nH]cc3C1=CCN(C)CC1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc(nc13)ccc1[nH]cc3C1=CCN(C)CC1)nc2)=O SEODMJGHAXQXJO-UHFFFAOYSA-N 0.000 description 1
- FRNSTUYJVHRNTP-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1c[n](cc(N3CCNCC3)[s]3)c3n1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1c[n](cc(N3CCNCC3)[s]3)c3n1)nc2)=O FRNSTUYJVHRNTP-UHFFFAOYSA-N 0.000 description 1
- ONLBWYHJGWHHFC-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(C(CC3)N(C4)CC44CCNCC4)c3c1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(C(CC3)N(C4)CC44CCNCC4)c3c1)nc2)=O ONLBWYHJGWHHFC-UHFFFAOYSA-N 0.000 description 1
- CYAITNITJNMZSM-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(CN(CC3)C4COC4)c3n1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(CN(CC3)C4COC4)c3n1)nc2)=O CYAITNITJNMZSM-UHFFFAOYSA-N 0.000 description 1
- FHIZZTKXDAJIAG-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(CNC3)c3n1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(CNC3)c3n1)nc2)=O FHIZZTKXDAJIAG-UHFFFAOYSA-N 0.000 description 1
- UZLZIXQWIPLVPE-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(cc(cc3)N4CCNCC4)c3n1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc(cc(cc3)N4CCNCC4)c3n1)nc2)=O UZLZIXQWIPLVPE-UHFFFAOYSA-N 0.000 description 1
- IXIHLYRHCXDTHN-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc3[nH]cc(C4CCN(C)CC4)c3c1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ccc3[nH]cc(C4CCN(C)CC4)c3c1)nc2)=O IXIHLYRHCXDTHN-UHFFFAOYSA-N 0.000 description 1
- RWJGPLUWRYTWRJ-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CCNC3)c3cc1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CCNC3)c3cc1)nc2)=O RWJGPLUWRYTWRJ-UHFFFAOYSA-N 0.000 description 1
- AXNDMBSWXSBTBE-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CC3)C4CCNCC4)c3cc1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CC3)C4CCNCC4)c3cc1)nc2)=O AXNDMBSWXSBTBE-UHFFFAOYSA-N 0.000 description 1
- WWLHQOBNDCJDCZ-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CC3)C4COC4)c3cc1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CC3)C4COC4)c3cc1)nc2)=O WWLHQOBNDCJDCZ-UHFFFAOYSA-N 0.000 description 1
- NGTOLNXYLMJDST-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CCN3CCNCC3)CC3)c3cc1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1nc(CN(CCN3CCNCC3)CC3)c3cc1)nc2)=O NGTOLNXYLMJDST-UHFFFAOYSA-N 0.000 description 1
- JSAKCRBUZUPURX-UHFFFAOYSA-N CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ncnc3c1[s]cc3C1=CCNCC1)nc2)=O Chemical compound CC(C(C(N1C2CCCC2)=O)=C(C)c2c1nc(Nc1ncnc3c1[s]cc3C1=CCNCC1)nc2)=O JSAKCRBUZUPURX-UHFFFAOYSA-N 0.000 description 1
- WVUFXUDMPNYSDC-UHFFFAOYSA-N CCN(CC1)Cc(cc2)c1nc2Nc(nc1)nc(N2C3CCCC3)c1C(C)=C(C(C)=O)C2=O Chemical compound CCN(CC1)Cc(cc2)c1nc2Nc(nc1)nc(N2C3CCCC3)c1C(C)=C(C(C)=O)C2=O WVUFXUDMPNYSDC-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410361634.X | 2014-07-26 | ||
| CN201410361634 | 2014-07-26 | ||
| CN201510076030 | 2015-02-12 | ||
| CN201510076030.5 | 2015-02-12 | ||
| PCT/CN2015/084984 WO2016015598A1 (en) | 2014-07-26 | 2015-07-23 | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524702A JP2017524702A (ja) | 2017-08-31 |
| JP2017524702A5 true JP2017524702A5 (OSRAM) | 2018-08-16 |
| JP6631616B2 JP6631616B2 (ja) | 2020-01-15 |
Family
ID=55192593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504046A Active JP6631616B2 (ja) | 2014-07-26 | 2015-07-23 | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9828373B2 (OSRAM) |
| EP (1) | EP3172214B1 (OSRAM) |
| JP (1) | JP6631616B2 (OSRAM) |
| KR (1) | KR20170032244A (OSRAM) |
| CN (3) | CN105294681B (OSRAM) |
| AU (1) | AU2015296322B2 (OSRAM) |
| CA (1) | CA2954189A1 (OSRAM) |
| WO (2) | WO2016015597A1 (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI574957B (zh) | 2011-07-29 | 2017-03-21 | 佳佑製藥治療公司 | 含有醯肼的核運輸調控子及其用途 |
| RS58058B1 (sr) | 2012-05-09 | 2019-02-28 | Biogen Ma Inc | Modulatori nukleusnog transporta i njihove upotrebe |
| DK3010892T3 (en) | 2013-06-21 | 2019-04-15 | Karyopharm Therapeutics Inc | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
| EP3386981B1 (en) * | 2015-12-13 | 2021-10-13 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
| WO2017117535A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| EP3397633A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| CN105777749A (zh) * | 2016-04-06 | 2016-07-20 | 中国药科大学 | 吡啶并嘧啶类化合物、其制备方法及其用途 |
| CN105968109B (zh) * | 2016-05-13 | 2017-11-17 | 聂红梅 | 一种制备帕博西尼中间体的方法 |
| JP2019516767A (ja) * | 2016-05-23 | 2019-06-20 | イーライ リリー アンド カンパニー | 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ |
| CN106083844B (zh) * | 2016-06-05 | 2017-11-10 | 陈志明 | 一种制备抗乳腺癌药物帕博西尼中间体的方法 |
| WO2018001270A1 (en) * | 2016-06-30 | 2018-01-04 | Noratech Pharmaceuticals, Inc. | Palbociclib prodrugs and composition thereof |
| BR112019005526A2 (pt) | 2016-10-20 | 2019-06-18 | Pfizer | agentes antiproliferativos para tratamento de pah |
| CA3043681A1 (en) * | 2016-11-16 | 2018-05-24 | Pfizer Inc. | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
| ES2852123T3 (es) * | 2016-11-28 | 2021-09-13 | Teijin Pharma Ltd | Derivados de ((piridin-2-il)-amino)pirido[3,4-d]pirimidina y ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina como inhibidores de CDK4/6 para tratar p. ej. artritis reumatoide, arteriosclerosis, fibrosis pulmonar, infarto cerebral o cáncer |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| JP7044801B2 (ja) * | 2016-12-16 | 2022-03-30 | シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッド | Ｃｄｋ４／６阻害剤 |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US20190388407A1 (en) | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| CN108929324A (zh) * | 2017-05-22 | 2018-12-04 | 南开大学 | 新型1,1-环丙基二酰胺衍生物的制备与应用 |
| AU2018281316B2 (en) * | 2017-06-07 | 2024-05-30 | Precigen, Inc. | Expression of novel cell tags |
| CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
| CN109394767A (zh) * | 2017-12-19 | 2019-03-01 | 清华大学 | 化合物在制备药物中的用途 |
| BR112020015431A2 (pt) | 2018-02-15 | 2020-12-08 | Nuvation Bio Inc. | Compostos heterocíclicos como inibidores de quinase |
| US20210214358A1 (en) | 2018-04-24 | 2021-07-15 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Cdk4/6 inhibitor and pharmaceutically acceptable salt and polymorph thereof and use thereof |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| CN108524938B (zh) * | 2018-06-15 | 2020-06-19 | 深圳大学 | Cdk6小分子抑制剂在降低肝癌细胞对抗肿瘤药或放疗的耐受性中的应用 |
| WO2020006210A1 (en) * | 2018-06-27 | 2020-01-02 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
| SG11202100429TA (en) | 2018-07-27 | 2021-02-25 | California Inst Of Techn | Cdk inhibitors and uses thereof |
| JP2021534153A (ja) * | 2018-08-15 | 2021-12-09 | アイビバ バイオファーマ インコーポレイテッド | Ｖｅｇｆおよびｔｇｆベータのマルチキナーゼ阻害剤およびその使用 |
| CN113272303B (zh) * | 2018-11-30 | 2024-09-17 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| WO2020114519A1 (zh) * | 2018-12-07 | 2020-06-11 | 杭州英创医药科技有限公司 | 作为cdk-hdac双通路抑制剂的杂环化合物 |
| ES2994095T3 (en) * | 2019-02-27 | 2025-01-17 | Astrazeneca Ab | Saracatinib for use in the treatment of idiopathic pulmonary fibrosis |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| TW202237585A (zh) | 2020-11-27 | 2022-10-01 | 瑞士商瑞森製藥公司 | Ｃｄｋ抑制劑 |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN114907339B (zh) * | 2021-02-08 | 2023-07-14 | 成都奥睿药业有限公司 | 4-（4-氨基苯氧基）吡啶-2-胺衍生物及其用途 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| CN114306255B (zh) * | 2021-12-30 | 2023-05-23 | 北京鑫开元医药科技有限公司 | 一种甲基酮类衍生物药物制剂及其制备方法 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
| CN119451967A (zh) * | 2022-06-22 | 2025-02-14 | 霖康疗法公司 | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物的双功能化合物 |
| WO2024107730A1 (en) * | 2022-11-14 | 2024-05-23 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| WO2024173833A1 (en) * | 2023-02-16 | 2024-08-22 | Mei Pharma, Inc. | Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| JP4548642B2 (ja) | 1998-09-29 | 2010-09-22 | アメリカン・サイアナミド・カンパニー | プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン |
| AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| JP4411709B2 (ja) | 1999-11-02 | 2010-02-10 | 凸版印刷株式会社 | キノロン誘導体ならびにそれを使用した有機ｅｌ素子 |
| WO2001044257A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
| AU2001234690A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa |
| SK12472002A3 (sk) | 2000-03-06 | 2003-04-01 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz |
| ATE408613T1 (de) | 2000-08-04 | 2008-10-15 | Warner Lambert Co | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3- d)pyrimidin-7-one |
| US6506749B2 (en) | 2000-08-31 | 2003-01-14 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (I) |
| CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
| AU2002256615B2 (en) | 2001-02-12 | 2007-09-13 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| JP4291696B2 (ja) | 2002-01-22 | 2009-07-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン |
| PA8577501A1 (es) | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| JP4053073B2 (ja) * | 2003-07-11 | 2008-02-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 選択的ｃｄｋ４阻害剤のイセチオン酸塩 |
| EP1673343A4 (en) | 2003-10-08 | 2008-09-10 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| DE602005002562T2 (de) | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| CA2575804A1 (en) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
| US20090131430A1 (en) | 2004-11-23 | 2009-05-21 | Palle Venkata P | Pyrido'2,3-dipyrimidines as anti-inflammatory agents |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| US20090036472A1 (en) | 2005-02-02 | 2009-02-05 | Palle Venkata P | Azabicyclo derivatives as anti-inflammatory agents |
| JP5480503B2 (ja) | 2005-10-07 | 2014-04-23 | エクセリクシス， インク． | ＰＩ３Ｋαのピリドピリミジノン型阻害剤 |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| US7998978B2 (en) | 2006-05-01 | 2011-08-16 | Pfizer Inc. | Substituted 2-amino-fused heterocyclic compounds |
| EP2018167A4 (en) | 2006-05-15 | 2010-07-14 | Irm Llc | COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES |
| HRP20110621T2 (hr) | 2006-09-15 | 2013-12-06 | Pfizer Products Inc. | SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3 |
| EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| CN101535308A (zh) | 2006-11-09 | 2009-09-16 | 霍夫曼-拉罗奇有限公司 | 作为激酶抑制剂的取代的6-苯基-吡啶并[2，3-d]嘧啶-7-酮衍生物及其使用方法 |
| EP2142543B8 (en) | 2007-04-11 | 2013-07-03 | Exelixis, Inc. | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| WO2009132980A1 (en) | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | Pyrimidinyl pyridone inhibitors of jnk. |
| CN101747306B (zh) | 2008-11-28 | 2012-08-29 | 中国中化股份有限公司 | 取代醚类化合物及其应用 |
| EP3718560A3 (en) * | 2009-05-13 | 2020-12-09 | The University of North Carolina at Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| CA2776770A1 (en) | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| WO2011075616A1 (en) | 2009-12-18 | 2011-06-23 | Temple University - Of The Commonwealth System Of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
| US20130035336A1 (en) * | 2010-04-13 | 2013-02-07 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer |
| WO2011156646A2 (en) | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011156786A2 (en) | 2010-06-10 | 2011-12-15 | Afraxis, Inc. | 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| EP2580216A4 (en) | 2010-06-10 | 2014-07-23 | Afraxis Holdings Inc | 8- (SULFONYLBENZYL) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| BR112013002375B1 (pt) | 2010-08-05 | 2020-05-12 | Temple University - Of The Commonwealth System Of Higher Education | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| MY161199A (en) * | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| BR112013025798A2 (pt) | 2011-04-08 | 2016-12-20 | Afraxis Holdings Inc | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para o tratamento de câncer e distúrbios de sistema nervoso |
| CA2854471A1 (en) | 2011-11-04 | 2013-05-10 | Afraxis Holdings, Inc. | Pak inhibitors for the treatment of cell proliferative disorders |
| US9670213B2 (en) | 2012-05-14 | 2017-06-06 | East China University Of Science And Technology | Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor |
| US9701638B2 (en) | 2012-11-09 | 2017-07-11 | Rutgers, The State University Of New Jersey | Therapeutic hydroxyquinolones |
| CN103012399B (zh) | 2012-11-22 | 2015-06-17 | 中国科学院广州生物医药与健康研究院 | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 |
| TW201522332A (zh) | 2013-03-01 | 2015-06-16 | Amgen Inc | 經取代之７－酮基－吡啶并［２，３－ｄ］嘧啶及其使用方法 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| JP2016512831A (ja) | 2013-03-15 | 2016-05-09 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたパルボシクリブ |
| WO2014174745A1 (ja) | 2013-04-26 | 2014-10-30 | 国立大学法人京都大学 | Ｅｇ５阻害剤 |
| US20140323477A1 (en) | 2013-04-30 | 2014-10-30 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| US20140323478A1 (en) | 2013-04-30 | 2014-10-30 | Afraxis Holdings, Inc. | Serine/threonine kinase inhibitors |
| EP2994470B1 (en) | 2013-05-09 | 2018-04-18 | Principia Biopharma Inc. | Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors |
| CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| EP2813504A1 (en) | 2013-06-14 | 2014-12-17 | Institut Quimic De Sarriá Cets, Fundació Privada | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof |
| TW201516045A (zh) | 2013-07-26 | 2015-05-01 | Hoffmann La Roche | 絲胺酸／蘇胺酸激酶抑制劑 |
| CN104418860B (zh) | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
| AU2014339972B9 (en) | 2013-10-25 | 2019-05-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US20160304466A1 (en) | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| CN105814022B (zh) | 2013-12-09 | 2018-09-28 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合的二环杂芳族衍生物 |
| BR112016017137B1 (pt) | 2014-02-07 | 2022-10-11 | Principia Biopharma, Inc | Composto e/ou sal farmaceuticamente aceitável do mesmo e composições farmacêuticas |
-
2015
- 2015-07-23 AU AU2015296322A patent/AU2015296322B2/en active Active
- 2015-07-23 CA CA2954189A patent/CA2954189A1/en not_active Abandoned
- 2015-07-23 US US15/318,366 patent/US9828373B2/en active Active
- 2015-07-23 CN CN201510439329.2A patent/CN105294681B/zh active Active
- 2015-07-23 WO PCT/CN2015/084983 patent/WO2016015597A1/en not_active Ceased
- 2015-07-23 KR KR1020167037000A patent/KR20170032244A/ko not_active Withdrawn
- 2015-07-23 WO PCT/CN2015/084984 patent/WO2016015598A1/en not_active Ceased
- 2015-07-23 CN CN201510439488.2A patent/CN105294682B/zh active Active
- 2015-07-23 EP EP15828004.0A patent/EP3172214B1/en active Active
- 2015-07-23 JP JP2017504046A patent/JP6631616B2/ja active Active
- 2015-07-24 CN CN201510443167.XA patent/CN105294736B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524702A5 (OSRAM) | ||
| JP2017520607A5 (OSRAM) | ||
| JP7696443B2 (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| AU2005274384B2 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| KR102148681B1 (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 | |
| CA2780190C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| KR102148679B1 (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| AU2017286654A1 (en) | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| JP2016515098A5 (OSRAM) | ||
| KR20180097530A (ko) | 단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법 | |
| TW201819386A (zh) | Shp2磷酸酶抑制劑及其使用方法 | |
| JP2019501222A5 (OSRAM) | ||
| JP2017528524A5 (OSRAM) | ||
| JP2012511588A5 (OSRAM) | ||
| JP2015523390A (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| CA2918813A1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases | |
| JP2015523390A5 (OSRAM) | ||
| KR20180013851A (ko) | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 | |
| JP2015530975A5 (OSRAM) | ||
| JP2020516604A (ja) | 抗がん併用療法 | |
| JP2016509056A5 (OSRAM) | ||
| JP2020515600A (ja) | 抗がん併用療法 | |
| CN107683138A (zh) | 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途 | |
| JP2015500884A5 (OSRAM) |